A5052154004- Head and Neck Cancer Studies
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Head and Neck Surgical Oncology
- Salivary Gland Tumors Diagnosis and Treatment
- Ear and Head Tumors
- Lung Cancer Research Studies
- CAR-T cell therapy research
- Cancer Diagnosis and Treatment
- Nonmelanoma Skin Cancer Studies
- Colorectal and Anal Carcinomas
- Thyroid Cancer Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Hedgehog Signaling Pathway Studies
- Immunotherapy and Immune Responses
- PI3K/AKT/mTOR signaling in cancer
- Radiopharmaceutical Chemistry and Applications
- Advanced Breast Cancer Therapies
- Tumors and Oncological Cases
- Oral and Maxillofacial Pathology
- Cancer, Hypoxia, and Metabolism
- Brain Metastases and Treatment
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research
Memorial Sloan Kettering Cancer Center
2016-2025
Cornell University
2015-2024
CancerCare
2024
Memorial Hospital
2020-2023
Kettering University
2017-2023
Weill Cornell Medicine
2017-2021
University of Pennsylvania
2008-2009
National Cancer Institute
2004
Center for Cancer Research
2004
Royal Preston Hospital
1996
No systemic therapies have been approved for the treatment of advanced cutaneous squamous-cell carcinoma. This cancer may be responsive to immune therapy, because mutation burden tumor is high and disease risk strongly associated with immunosuppression. In dose-escalation portion phase 1 study cemiplimab, a deep durable response was observed in patient metastatic carcinoma.We report results cemiplimab expansion cohorts patients locally or carcinoma, as well pivotal 2 cohort...
The objective response rate (ORR) for single-agent anti-programmed death receptor 1 (anti-PD-1) therapy is modest in patients with metastatic or recurrent head and neck squamous cell carcinoma (HNSCC). We aimed to test whether radiotherapy may act synergistically anti-PD-1 improve through the abscopal effect.We conducted a single-center, randomized, phase II trial of nivolumab (anti-PD-1 therapy) versus plus stereotactic body (SBRT) HNSCC. Patients had at least two lesions: one that could be...
PURPOSE Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer commonly driven by the polyomavirus (MCPyV). The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway often upregulated in MCC, and advanced metastatic MCC frequently responds to PD-1 blockade. We report what we believe be first trial of anti–PD-1 neoadjuvant setting for resectable MCC. METHODS In phase I/II CheckMate 358 study virus-associated types, patients with received nivolumab 240 mg...
BRAFV600E mutant thyroid cancers are often refractory to radioiodine (RAI). To investigate the utility and molecular underpinnings of enhancing lesional iodide uptake with BRAF inhibitor vemurafenib in patients RAI-refractory (RAIR). This was a pilot trial that enrolled from June 2014 January 2016. Academic cancer center. Patients RAIR, cancer. underwent thyrotropin-stimulated iodine-124 (124I) positron emission tomography scans before after ~4 weeks vemurafenib. Those increased RAI...
PURPOSE Recurrent or metastatic adenoid cystic carcinoma (R/M ACC) is a malignant neoplasm of predominantly salivary gland origin for which effective therapies are lacking. We conducted phase II trial evaluating the multitargeted tyrosine kinase inhibitor lenvatinib in patients with R/M ACC. PATIENTS AND METHODS This study was two-stage minimax design. Patients histologically confirmed ACC any primary site radiographic and/or symptomatic progression were eligible. Any prior therapy allowed...
Even though 15% to 50% of patients with head and neck squamous cell carcinoma (HNSCC) experience recurrence, relatively little is known regarding patterns treatment failure postrecurrence outcomes after chemoradiotherapy using modern radiation techniques (intensity-modulated radiotherapy [IMRT]). Recurrence are significantly affected by variations in the quality radiotherapy, which may confound findings from multicenter trials.To assess for HNSCC treated contemporary techniques.This large...
Background Cemiplimab, a high-affinity, potent human immunoglobulin G4 monoclonal antibody to programmed cell death-1 demonstrated antitumor activity in Phase 1 advanced cutaneous squamous carcinoma (CSCC) expansion cohort ( NCT02383212 ) and the pivotal 2 study NCT02760498 ). Here we report primary analysis of fixed dose cemiplimab 350 mg intravenously every 3 weeks (Q3W) (Group 3) provide longer-term update after weight-based mg/kg (Q2W) 1) among metastatic CSCC (mCSCC) patients Methods...
About 50% of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) experience recurrences after definitive therapy. The presurgical administration anti-programmed death protein 1 (PD-1) immunotherapy results in substantial pathologic tumor responses (pTR) within the microenvironment (TME). However, mechanisms underlying dynamics antitumor T cells upon neoadjuvant PD-1 blockade remain unresolved, approaches to increase are lacking. In a phase 2 trial (NCT02296684), we...
PURPOSE Standard curative-intent chemoradiotherapy for human papillomavirus (HPV)–related oropharyngeal carcinoma results in significant toxicity. Since hypoxic tumors are radioresistant, we posited that the aerobic state of a tumor could identify patients eligible de-escalation while maintaining treatment efficacy. METHODS We enrolled with HPV-related to receive de-escalated definitive phase II study (ClinicalTrials.gov identifier: NCT03323463 ). Patients first underwent surgical removal...
Study Objective. The primary objective was to analyze the relationship between citation rate of an article and extent collaboration. secondary number authors/article institutions/article for period study. Methods. We counted original research articles published in six leading journals—Cell, Science, Nature, New England Journal Medicine, Lancet, American Medical Association—for years 1975, 1985, 1995. For each article, we determined authors separate institutions. also times that 1995 cited...
<h3>Importance</h3> Several de-escalation strategies for human papillomavirus (HPV)–associated oropharyngeal carcinoma (OPC) have focused on deintensifying gross disease treatment. Reduction of radiotherapy dose and target volume to subclinical regions may achieve good clinical outcomes with favorable patient quality life (QOL). <h3>Objective</h3> To determine from a systematic approach reducing the elective treatment in patients HPV-associated OPC undergoing concurrent chemoradiotherapy...
Background: Oncogenic activation of mitogen-activated protein kinase (MAPK) signaling is associated with radioiodine refractory (RAIR) thyroid cancer. Preclinical models suggest that the receptor tyrosine erbB-3 (HER3) mitigates MAPK pathway inhibition achieved by BRAF inhibitors in BRAFV600E mutant cancers. We hypothesized combined and HER3 using vemurafenib human monoclonal antibody CDX-3379, respectively, would potently inhibit restore radioactive iodine (RAI) avidity patients BRAF-mutant...
Importance Use of proton therapy reirradiation (PT-ReRT) for head and neck cancer is increasing; however, reports are heterogenous outcomes can be difficult to interpret. Objective To evaluate toxic effects following PT-ReRT in a uniform consecutive cohort patients with squamous cell carcinoma. Design, Setting, Participants This retrospective study included recurrent primary carcinoma who were treated from January 1, 2013, December 31, 2020, at single institution. Patient, clinical,...
Adenoid cystic carcinoma (ACC) is the second most common salivary gland malignancy and it has a high rate of recurrences poor long-term prognosis. Our aim was to assess prognostic factors in ACC study MYB-NFIB fusion MYB protein expression large retrospective cohort 135 patients with median follow-up 6.3 years. The 5- 10-year local recurrence-free survival (RFS) 94% 78%, distant metastasis 77% 58%, RFS 66% 44%. following features were identified as adverse on univariate analysis: tumor size,...
BACKGROUND Patients with recurrent and/or metastatic, radioactive iodine‐refractory thyroid carcinoma have limited treatment options. Sorafenib, an oral kinase inhibitor, is approved by the US Food and Drug Administration for of carcinoma, although it demonstrated low response rates (12.2%) as a single agent in first‐line setting. The objective current study was to determine whether adding mammalian target rapamycin inhibitor temsirolimus sorafenib could improve on these results. METHODS In...
6009 Background: A minority of patients with metastatic HNSCC respond to the anti-programmed death (PD-1) monoclonal antibody, Nivolumab (Nivo). We sought determine whether targeted radiation a single lesion combined Nivo would enhance tumor regression in non-irradiated lesions (abscopal response) and improve outcomes. Methods: Patients M1 (including nasopharynx) at least two RECIST 1.1 measurable were randomized stratification for viral status (EBV/HPV pos vs. neg) 1:1 either alone q 2...
<h3>Importance</h3> Patients with nonmetastatic nasopharyngeal carcinoma (NPC) are primarily treated by radiotherapy curative intent or without chemotherapy and often experience substantial treatment-related toxic effects even modern radiation techniques, such as intensity-modulated therapy (IMRT). Intensity-modulated proton (IMPT) may improve the toxicity profile; however, there is a paucity of data given limited availability IMPT in regions endemic NPC. <h3>Objective</h3> To compare...
Importance Patients with oropharyngeal carcinoma (OPC) treated radiotherapy often experience substantial toxic effects, even modern techniques such as intensity-modulated radiation therapy (IMRT). Intensity-modulated proton (IMPT) has a potential advantage over IMRT due to reduced dose the surrounding organs at risk; however, data are scarce given limited availability and use of IMPT. Objective To compare effects oncologic outcomes among patients newly diagnosed nonmetastatic OPC IMPT vs or...
Locally advanced, unresectable basal cell carcinoma (LA BCC) can be treated with radiation therapy (RT), but locoregional control (LRC) rates are unsatisfactory. Vismodegib is a hedgehog pathway inhibitor (HPI) active in BCC that may radiosensitize BCC. We evaluated the combination of vismodegib and RT for patients LA